BRPI0513914A - uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais - Google Patents

uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais

Info

Publication number
BRPI0513914A
BRPI0513914A BRPI0513914-7A BRPI0513914A BRPI0513914A BR PI0513914 A BRPI0513914 A BR PI0513914A BR PI0513914 A BRPI0513914 A BR PI0513914A BR PI0513914 A BRPI0513914 A BR PI0513914A
Authority
BR
Brazil
Prior art keywords
alk
animals
modulate
inhibitors
myostatin activity
Prior art date
Application number
BRPI0513914-7A
Other languages
English (en)
Inventor
David G Sawutz
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of BRPI0513914A publication Critical patent/BRPI0513914A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

USO DE INIBIDORES DO ALK 5 PARA MODULAR OU INIBIR A ATIVIDADE DA MIOSTATINA ACARRETANDO UM ACRéSCIMO MAIOR DE TECIDO MAGRO EM ANIMAIS. A presente invenção refere-se a métodos para aumento de tecido muscular em animais. Em um aspecto, o método inclui a administração de uma quantidade efetiva de um inibidor do receptor ALK 5 tal como a um animal por um tempo suficiente para causar o efeito desejado.
BRPI0513914-7A 2004-07-29 2005-07-27 uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais BRPI0513914A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59235904P 2004-07-29 2004-07-29
PCT/US2005/026607 WO2006025988A1 (en) 2004-07-29 2005-07-27 Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals

Publications (1)

Publication Number Publication Date
BRPI0513914A true BRPI0513914A (pt) 2008-05-20

Family

ID=35595039

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513914-7A BRPI0513914A (pt) 2004-07-29 2005-07-27 uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais

Country Status (14)

Country Link
US (1) US20060194845A1 (pt)
EP (1) EP1771171A1 (pt)
JP (1) JP2008506787A (pt)
CN (1) CN101031294A (pt)
AR (1) AR050187A1 (pt)
AU (1) AU2005280496B2 (pt)
BR (1) BRPI0513914A (pt)
CA (1) CA2576734C (pt)
MX (1) MX2007001118A (pt)
NO (1) NO20071113L (pt)
PE (1) PE20060729A1 (pt)
TW (1) TW200616621A (pt)
WO (1) WO2006025988A1 (pt)
ZA (1) ZA200700681B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
US20100144865A1 (en) * 2007-05-04 2010-06-10 Jana Pickova Compound feed for aquaculture
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101684457B (zh) * 2009-07-27 2013-01-09 中国科学院广州生物医药与健康研究院 I型转化生长因子受体抑制剂在产生诱导多能干细胞中的应用及其方法
CA2831827A1 (en) * 2011-04-05 2012-10-11 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
EP3711771A1 (en) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2022511112A (ja) 2018-12-11 2022-01-28 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
AU2020385400A1 (en) 2019-11-22 2022-06-09 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as ALK5 inhibitors
WO2022104071A2 (en) * 2020-11-13 2022-05-19 The Jackson Laboratory Therapeutics targeting transforming growth factor beta family signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1147413B1 (en) * 1999-01-21 2006-04-05 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
ES2187473T3 (es) * 1999-04-09 2003-06-16 Smithkline Beecham Corp Triarylimidazoles.
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
AU2005280496B2 (en) 2009-10-08
WO2006025988A1 (en) 2006-03-09
PE20060729A1 (es) 2006-08-12
CN101031294A (zh) 2007-09-05
CA2576734A1 (en) 2006-03-09
NO20071113L (no) 2007-02-27
TW200616621A (en) 2006-06-01
US20060194845A1 (en) 2006-08-31
CA2576734C (en) 2010-03-16
JP2008506787A (ja) 2008-03-06
ZA200700681B (en) 2008-07-30
MX2007001118A (es) 2007-03-15
AU2005280496A1 (en) 2006-03-09
AR050187A1 (es) 2006-10-04
EP1771171A1 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
BRPI0513914A (pt) uso de inibidores do alk 5 para modular ou inibir a atividade da miostatina acarretando um acréscimo maior de tecido magro em animais
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
NI200700040A (es) Analogos de biaril piperazinil-piridina sustituidos
ATE550031T1 (de) Zusammensetzungen und verfahren für die lipomodellierung
BRPI0510808A (pt) derivados de benzonitrila para tratar fragilidade musculoesquelética
BRPI0411241A (pt) agentes terapêuticos úteis para o tratamento de dor
CY1116450T1 (el) Παρασιτοκτονες ενωσεις διυδροϊσοξαζολιου
BRPI0909037B8 (pt) compostos moduladores da atividade de tlr, e composição farmacêutica
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
CY1108422T1 (el) Παραγωγα 4-τετραζολυλ-4φαινυλπιπεριδινης για θεραπεια πονου
AR060089A1 (es) Tratamiento del dolor
BRPI0512274A (pt) derivados de piperazina aril-substituìdos
BRPI0607536A2 (pt) tratamento de dor
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
BRPI0911031B8 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
BR0308813A (pt) Tratamento de tuberculose usando derivados de pleuromutilina
BRPI0916540B8 (pt) inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos
HRP20140896T1 (hr) (-)-stereoizomer 2,6-di-sec-butilfenola i njegovi analozi za poticanje antiemetskog uäśinka, lijeäśenje muäśnine i povraä†anja, te lijeäśenje migrene

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 7A ANUIDADE.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/4439 (2006.01), A23K 20/111 (2016.01), A23